首页> 外文期刊>Seminars in liver disease >Hepatotoxicity of nucleoside reverse transcriptase inhibitors.
【24h】

Hepatotoxicity of nucleoside reverse transcriptase inhibitors.

机译:核苷逆转录酶抑制剂的肝毒性。

获取原文
获取原文并翻译 | 示例
       

摘要

Hepatotoxicity is an adverse effect of all available classes of antiretrovirals, including nucleoside reverse transcriptase inhibitors (NRTI). A syndrome of hepatic steatosis and lactic acidosis has been recognized as a rare, potentially fatal complication since the advent of NRTI monotherapy in the early 1990s. Today, NRTI remain the backbone of antiretroviral combination regimens, and, with the success of current treatment strategies, exposure to two or more of these agents may occur over a number of years. Hepatic steatosis and lactic acidosis are accordingly being observed more frequently, along with a more recently recognized syndrome of chronic hyperlactatemia. These as well as other adverse effects of NRTI are mediated by inhibition of human DNA polymerase gamma, resulting in mitochondrial dysfunction in the liver and other tissues. Early recognition and intervention are essential to avert serious outcomes.
机译:肝毒性是所有可用类别的抗逆转录病毒药物(包括核苷逆转录酶抑制剂(NRTI))的不利影响。自1990年代初期NRTI单一疗法问世以来,肝脂肪变性和乳酸性酸中毒综合征已被认为是一种罕见的,可能致命的并发症。如今,NRTI仍然是抗逆转录病毒药物联合治疗方案的骨干力量,并且随着当前治疗策略的成功,多年来可能会接触两种或多种这些药物。因此,人们越来越频繁地观察到肝脂肪变性和乳酸性酸中毒,以及最近认识到的慢性高乳酸血症综合征。 NRTI的这些以及其他不利影响是通过抑制人类DNA聚合酶γ介导的,导致肝脏和其他组织中的线粒体功能障碍。早期识别和干预对于避免严重后果至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号